N-(6-methylpyridin-2-yl)quinolin-2-amine | 324526-73-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N-(6-methylpyridin-2-yl)quinolin-2-amine
• 英文别名: N-(6-Methyl-2-pyridinyl)-2-quinolinamine
• CAS: 324526-73-0
• 化学式: C₁₅H₁₃N₃
• 分子量: 235.288
• InChiKey: ZTKSVFASFFNDNT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  37.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-氨基-6-甲基吡啶 、 2-氯喹啉 在 palladium diacetate 、 caesium carbonate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 叔丁醇 为溶剂， 反应 10.0h， 以49%的产率得到N-(6-methylpyridin-2-yl)quinolin-2-amine
  参考文献：
  名称：

  Discovery of N-(Pyridin-4-yl)-1,5-naphthyridin-2-amines as Potential Tau Pathology PET Tracers for Alzheimer’s Disease

  摘要：

  A mini-HTS on 4000 compounds selected using 2D fragment-based similarity and 3D pharmacophoric and shape similarity to known selective tau aggregate binders identified N-(6-methylpyridin-2-yl)quinolin-2-amine 10 as a novel potent binder to human AD aggregated tau with modest selectivity versus aggregated beta-amyloid (A beta). Initial medicinal chemistry efforts identified key elements for potency and selectivity, as well as suitable positions for radiofluorination, leading to a first generation of fluoroalkyl-substituted quinoline tau binding ligands with suboptimal physicochemical properties. Further optimization toward a more optimal pharmacokinetic profile led to the discovery of 1,5-naphthyridine 75, a potent and selective tau aggregate binder with potential as a tau PET tracer.

  DOI：

  10.1021/acs.jmedchem.6b01173

文献信息

• [EN] BICYCLIC COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES<br/>[FR] COMPOSÉS BICYCLIQUES UTILES POUR LE TRAITEMENT DE MALADIES CAUSÉES PAR DES RÉTROVIRUS
  申请人：SPLICOS

  公开号：WO2015001518A1

  公开（公告）日：2015-01-08

  Described herein are methods for preventing or treating a retroviral infection and/or for preventing, inhibiting or treating a disease caused by the retroviral infection. In certain aspects, the methods described herein include contacting a cell in need thereof with compound (I), wherein (II) means a pyridazine, a pyrimidine or a pyrazine group, R independently represent a hydrogen atom, a halogen atom or a group chosen among a –CN group, a hydroxyl group, a –COOR1 group, a (C1 -C3)fluoroalkyl group, a (C1 -C3)fluoroalkoxy group, a –NO2 group, a –NR1R2 group, a (C1-C4)alkoxy group, a phenoxy group and a (C1-C3)alkyl group, said alkyl being optionally mono-substituted by a hydroxyl group, n is 1, 2 or 3, n' is 1 or 2, R' is a hydrogen atom, a halogen atom or a group chosen among a (C1-C3)alkyl group,, a hydroxyl group, a –COOR1 group, a –NO2 group, a –NR1R2 group, a morpholinyl or a morpholino group, a N-methylpiperazinyl group, a (C1-C3)fluoroalkyl group, a (C1-C4)alkoxy group and a –CN group, Z is N or C, Y is N or C, X is N or C, W is N or C, T is N or C, U is N or C, to prevent or treat the retroviral infection and/or for preventing, inhibiting or treating a disease caused by the retroviral infection, wherein the retroviral infection is not HIV and the disease caused by the retroviral infection is not AIDS.

  本文描述了一种预防或治疗逆转录病毒感染和/或预防、抑制或治疗由逆转录病毒感染引起的疾病的方法。在某些方面，所述方法包括将化合物(I)与需要其治疗的细胞接触，其中(II)表示吡啶嗪、嘧啶或吡嗪基团，R独立地表示氢原子、卤素原子或在-CN基团、羟基基团、-COOR1基团、(C1-C3)氟代烷基团、(C1-C3)氟代烷氧基团、-NO2基团、-NR1R2基团、(C1-C4)烷氧基团、苯氧基团和(C1-C3)烷基团中选择的一种基团，所述烷基可以选择性地被羟基基团单取代，n为1、2或3，n'为1或2，R'为氢原子、卤素原子或在(C1-C3)烷基团、羟基基团、-COOR1基团、-NO2基团、-NR1R2基团、吗啉基或吗啉基团、N-甲基哌嗪基团、(C1-C3)氟代烷基团、(C1-C4)烷氧基团和-CN基团中选择的一种基团，Z为N或C，Y为N或C，X为N或C，W为N或C，T为N或C，U为N或C，以预防或治疗逆转录病毒感染和/或预防、抑制或治疗由逆转录病毒感染引起的疾病，其中逆转录病毒感染不是HIV，由逆转录病毒感染引起的疾病不是艾滋病。
• COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA
  申请人：Tazi Jamal

  公开号：US20120329796A1

  公开（公告）日：2012-12-27

  The present invention relates to compound (I) wherein: means a pyridazine, a pyrimidine or a pyrazine group, R independently represent a hydrogen atom, a halogen atom or a group chosen among a —CN group, a hydroxyl group, a —COOR 1 group, a (C 1 -C 3 )fluoroalkyl group, a (C 1 -C 3 )fluoroalkoxy group, a —NO2 group, a —NRiR2 group, a (C 1 -C 4 )alkoxy group, a phenoxy group and a (C 1 -C 3 )alkyl group, said alkyl being optionally mono-substituted by a hydroxyl group, n is 1, 2 or 3, n′ is 1 or 2, R′ is a hydrogen atom, a halogen atom or a group chosen among a (Ci-C3)alkyl group, a hydroxyl group, a —COOR 1 group, a —NO2 group, a —NR 1 R 2 group, a morpholinyl or a morpholino group, a N-methylpiperazinyl group, a (Ci-C3)fluoroalkyl group, a (C 1 -C 4 )alkoxy group and a —CN group, Z is N or C, Y is N or C, X is N or C, W is N or C, T is N or C, U is N or C, for use as an agent for preventing, inhibiting or treating pathological or nonpathological conditions linked with premature aging. Some of said compounds are new and also form part of the invention.

  本发明涉及化合物(I)，其中：表示吡啶嗪、嘧啶或吡嗪基团，R独立地表示氢原子、卤素原子或在-CN基团、羟基基团、-COOR1基团、(C1-C3)氟烷基团、(C1-C3)氟烷氧基团、-NO2基团、-NRiR2基团、(C1-C4)烷氧基团、苯氧基团和(C1-C3)烷基团中选择的一种基团，所述烷基可以选择性地被一个羟基基团单取代，n为1、2或3，n'为1或2，R'为氢原子、卤素原子或在(Ci-C3)烷基团、羟基基团、-COOR1基团、-NO2基团、-NR1R2基团、吗啉基或吗啉基团、N-甲基哌嗪基团、(Ci-C3)氟烷基团、(C1-C4)烷氧基团和-CN基团中选择的一种基团，Z为N或C，Y为N或C，X为N或C，W为N或C，T为N或C，U为N或C，用作预防、抑制或治疗与早衰有关的病理或非病理状态的药剂。其中一些化合物是新的，也是本发明的一部分。
• QUINOLINE DERIVATIVES FOR USE INE THE TRAEATMENT OF INFLAMMATION DISEASES
  申请人：ABIVAX

  公开号：EP3669873A1

  公开（公告）日：2020-06-24

  The present disclosure relates to quinoline derivatives of Formula (I): wherein each R is independently hydrogen, halogen, -CN, hydroxyl, (C1-C3)fluoroalkyl, (C1-C3)fluoroalkoxy, (C3-C6)cycloalkyl, -NO2, -NR1R2, (C1-C4)alkoxy, phenoxy, -NR1-SO2-NR1R2, -NR1-SO2-R1, -NR1-C(=O)-R1, -NR1-C(=O)-NR1R2,-SO2-NR1R2, -SO3H, -O-SO2-OR3, -O-P(=O)-(OR3)(OR4), -O-CH2-COOR3, (C1-C3)alkyl, said alkyl being optionally mono- or di-substituted by a hydroxyl group; each R' is independently hydrogen, (C1-C3)alkyl, hydroxyl, halogen, -NO2, -NR1R2, morpholinyl, morpholino, N-methylpiperazinyl, (C1-C3)fluoroalkyl, (C1-C4)alkoxy, -O-P(=O)-(OR3)(OR4), -CN, or other groups; for use for preventing and/or treating inflammatory disease, disorder, or conditions.

  本公开涉及式 (I) 的喹啉衍生物： 其中每个 R 独立地为氢、卤素、-CN、羟基、(C1-C3)氟烷基、(C1-C3)氟烷氧基、(C3-C6)环烷基、-NO2、-NR1R2、(C1-C4)烷氧基、苯氧基、-NR1-SO2-NR1R2、-NR1-SO2-R1、-NR1-C(＝O)-R1、-NR1-C(＝O)-NR1R2、-SO2-NR1R2、-SO3H、-O-SO2-OR3、-O-P(＝O)-(OR3)(OR4)、-O-CH2-COOR3、(C1-C3)烷基，所述烷基可任选被羟基单取代或二取代；每个 R'独立地为氢、(C1-C3)烷基、羟基、卤素、-NO2、-NR1R2、吗啉基、吗啉基、N-甲基哌嗪基、(C1-C3)氟烷基、(C1-C4)烷氧基、-O-P(=O)-(OR3)(OR4)、-CN 或其他基团；用于预防和/或治疗炎症性疾病、紊乱或病症。
• QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OR PREVENTION OF CANCER
  申请人：ABIVAX

  公开号：EP3669874A1

  公开（公告）日：2020-06-24

  A quinoline derivative of formula (I') wherein R independently represent a halogen atom or a group chosen among a (C1-C3)fluoroalkyl group, a (C1-C3)fluoroalkoxy group, a -NR1R2 group, a (C1-C4)alkoxy group and a (C1-C3)alkyl group, said alkyl being optionally mono or di-substituted by a hydroxyl group, R' independently represent a halogen atom or a group chosen among a (C1-C3)alkyl group, a hydroxyl group, a -NR1R2 group, a morpholinyl or a morpholino group, a N-methylpiperazinyl group, a (C1-C3)fluoroalkyl group and a (C1-C4)alkoxy group, and can further be a other groups or anyone of its metabolites or pharmaceutically acceptable salt or anyone of their enantiomers or diastereoisomers, for use for treating or preventing cancer or dysplasia.

  式 (I') 的喹啉衍生物 其中 R 独立地代表一个卤素原子或一个选自(C1-C3)氟烷基、(C1-C3)氟烷氧基、-NR1R2 基团、(C1-C4)烷氧基和(C1-C3)烷基的基团，所述烷基可选择被羟基单取代或二取代，R'独立地代表一个卤素原子或一个选自(C1-C3)烷基的基团、羟基、-NR1R2 基团、吗啉基或吗啉基、N-甲基哌嗪基、(C1-C3)氟烷基和(C1-C4)烷氧基，还可以是其他基团或其代谢物或药学上可接受的盐或其对映体或非对映异构体中的任何一种，用于治疗或预防癌症或发育不良。
• BIOMARKERS, AND USES IN TREATMENT OF VIRAL INFECTIONS, INFLAMMATIONS, OR CANCER
  申请人：ABIVAX

  公开号：EP3670659A1

  公开（公告）日：2020-06-24

  The present disclosure relates to certain biomarkers, and uses thereof in monitoring, assessing, and/or treatment of viral infections, or inflammatory diseases, disorders, or conditions, or cancer.

  本公开涉及某些生物标记物及其在监测、评估和/或治疗病毒感染或炎症性疾病、失调或病症或癌症中的用途。